CD93 serves as a potential biomarker of gastric cancer and correlates with the tumor microenvironment

Figure 2 Diagnostic and prognostic value analysis. A and B: Differential expression of CD93 between gastric cancer (GC) and normal tissues in unpaired samples (A), paired samples (B); C: Receiver operating characteristic (ROC) curve of overall survival based on CD93 in The Cancer Genome Atlas stomach adenocarcinoma; D: Kaplan-Meier analysis of OS between two groups; E: Immunohistochemistry of CD93 between GC and normal tissues; F: Immunofluorescence of CD93; H-K: Differential expression of CD93 in 4 validation datasets (GSE118916, GSE52138, GSE79973, and GSE19826); L-O: ROC curves of 4 validation datasets based on CD93.